quinazolines has been researched along with Genetic Predisposition in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (25.00) | 29.6817 |
| 2010's | 34 (70.83) | 24.3611 |
| 2020's | 2 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Arulananda, S; John, T; Loh, Z; Mitchell, P | 1 |
| Ang, GCK; Chang, KT; Guccione, E; Hebrard, M; Lee, VK; Leung, JY; Lim, HJ; Pal, A; Pignata, L; Rao, VK; Taneja, R | 1 |
| Chu, HW; Davis-Hall, D; Dobrinskikh, E; Magin, CM; Michalski, JE; Park, JA; Schwartz, DA; Smith, BJ; Stancil, IT; Yang, IV | 1 |
| Gotoda, H; Hotta, K; Ichihara, E; Ichimura, K; Kato, Y; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Ninomiya, K; Ohashi, K; Tamura, T; Tanaka, T | 1 |
| Hagiwara, K; Kondoh, Y; Lasky, JA; Saito, S | 1 |
| Bers, DM; Diecke, S; Gong, T; Knowles, JW; Lan, F; Lee, AS; Liang, P; Nguyen, PK; Robbins, RC; Sallam, K; Sanchez-Freire, V; Wang, PJ; Wang, Y; Wu, JC | 1 |
| Bontognali, S; Brutsche, MH; Buess, M; Fischer, C; Pless, M; Rochlitz, C | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| Blendy, JA; Everett, L; Jepson, C; Kaestner, KH; Lee, B; Lerman, C; Ray, R; Turner, JR; Xiang, J | 1 |
| Cardon, LR; Cox, CJ; Curran, J; Ejlertsen, B; Finkelstein, DM; Goss, PE; McDonnell, SK; Parham, LR; Rappold, E; Schaid, DJ; Spraggs, CF | 1 |
| Boehm, BO; Dugi, KA; Graefe-Mody, U; Ittrich, C; Mark, M; Woerle, HJ; Zimdahl, H | 1 |
| Becker, A; Heideman, DA; Kuiper, JL; Ronden, MI; Smit, EF; Thunnissen, E; van Hengel, P; Ylstra, B | 1 |
| Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Ito, K; Kinoshita, I; Kobayashi, K; Kurihara, M; Maemondo, M; Minato, K; Morita, S; Nishitsuji, M; Nukiwa, T; Oizumi, S; Sugawara, S; Yoshizawa, H | 1 |
| Ahn, MJ; Atagi, S; Jiang, H; Kim, SW; Lee, DH; Liu, Y; Lu, Y; Mok, TS; Nakagawa, K; Ponce, S; Shi, X; Soria, JC; Wang, J; Webster, A; Wu, YL; Yang, JC; Yang, JJ; Yoh, K; Zhou, JY | 1 |
| Briley, LP; Byrne, J; Goss, PE; King, KS; Parham, LR; Rappold, E; Spraggs, CF | 1 |
| Fu, F; Geng, J; Sun, D; Wang, H; Xie, X; Yu, G; Zhang, L | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, TM; Kim, YW; Lee, SH; Park, S; Suh, B | 1 |
| Kim, HR; Kim, JH; Kim, S; Kwack, K; Lee, MG; Lim, SM; Moon, YW; Park, HS | 1 |
| Cheng, M; Conteh, AM; Craven, KE; Gore, J; Imasuen-Williams, IE; Korc, M | 1 |
| Amici, A; Andreani, C; Bartolacci, C; Belletti, B; Elexpuru Zabaleta, M; Galeazzi, R; Gambini, V; Garulli, C; Hysi, A; Iezzi, M; Kalogris, C; Marchini, C; Orlando, F; Pietrella, L; Provinciali, M; Tilio, M; Wang, J | 1 |
| Dietel, M; Eberhardt, W; Griesinger, F; Radke, S; Schirmacher, P; Schuette, W; Thomas, M; Zirrgiebel, U | 1 |
| Aleksakhina, SN; Chubenko, VA; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Kozyreva, KS; Kramchaninov, MM; Mitiushkina, NV; Moiseyenko, FV; Moiseyenko, VM; Preobrazhenskaya, EV; Shelekhova, KV; Venina, AR; Volkov, NM; Zhuravlev, AS | 1 |
| Chai, Y; Yu, T; Zhu, Z | 1 |
| Azuma, A; Hagiwara, K; Kudoh, S | 1 |
| Benusiglio, PR | 1 |
| Muslimov, GF | 1 |
| Goto, Y; Hojo, M; Kobayashi, N; Kudo, K; Takeda, Y | 1 |
| Boggon, TJ; Cappuzzo, F; Clifford, B; Eisenberg, R; Franklin, WA; Fu, P; Halmos, B; Hamdan, A; Hirsch, FR; Jin, C; Leidner, RS; Skokan, M; Varella-Garcia, M | 1 |
| Gagel, RF; Gosnell, JE; Krebs, A; Moley, J; Pfister, D; Schlumberger, M; Skinner, M; Sosa, JA; Vasselli, J; Wells, SA | 1 |
| Wörmann, B | 1 |
| Chung, KP; Shih, JY; Yu, CJ | 1 |
| Bing, N; Briley, LP; Budde, LR; Cardon, LR; Cox, CJ; King, KS; Mooser, VE; Preston, AJ; Spraggs, CF; Stein, SH; Whittaker, JC | 1 |
| de Azambuja, E; Metzger-Filho, O | 1 |
| Andersen, JB; Avital, I; Barbour, A; Blechacz, BR; Conner, EA; Factor, VM; Gillen, MC; Komuta, M; Roberts, LR; Roskams, T; Spee, B; Thorgeirsson, SS | 1 |
| Ando, M; Hasegawa, Y; Horio, M; Horio, Y; Kondo, M; Saito, H; Tamura, M; Yamamoto, M | 1 |
| Bird, L; Fox, EA; Kopp, N; Lane, AA; Rodig, SJ; Shindoh, N; Sullivan, TJ; Weigert, O; Weinstock, DM; Yoda, A; Yoda, Y | 1 |
| García-Sanchez, R; Plaza, S; Ramirez, G | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Corominas-Faja, B; Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Urruticoechea, A; Vazquez-Martin, A | 1 |
| Allen, PK; Amini, A; Brown, P; Chang, JY; Chen, SS; Garland, LL; Heymach, JV; Holt, J; Kim, ES; Komaki, R; Liao, Z; McGovern, SL; Munsell, MF; Stea, B; Sulman, E; Unger, W; Wefel, JS; Welsh, JW | 1 |
| Amador, ML; Ashfaq, R; Baker, SD; Cusati, G; Cusatis, G; Forastiere, A; Hidalgo, M; Iacobuzio-Donahue, C; Maitra, A; Oppenheimer, D; Perea, S; Takimoto, C | 1 |
| Altavilla, G; Rosell, R; Salazar, F; Santarpia, M; Tarón, M | 1 |
| Kudo, S | 1 |
| Eguchi, K; Hisamoto, A; Kiura, K; Kozuki, T; Mandai, K; Nakata, M; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Guo, AL; Wang, Z; Wu, YL; Xu, CR; Zhang, GC; Zhou, Q | 1 |
| Adjei, AA; Cassivi, SD; Molina, JR; Schild, SE; Yang, P | 1 |
| Andress, L; Bridges, AJ; Burgart, LJ; Fry, DW; Gendler, SJ; Karnes, WE; Nelson, JM; Ritland, SR | 1 |
7 review(s) available for quinazolines and Genetic Predisposition
| Article | Year |
|---|---|
Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective.
Topics: Asian People; Cause of Death; Disease Progression; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Japan; Lung Neoplasms; Male; Pneumonectomy; Prevalence; Prognosis; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Survival Rate | 2018 |
[Oncology 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2010 |
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Belgium; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Cholangiocarcinoma; Cluster Analysis; ErbB Receptors; Female; Gene Expression Profiling; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Laser Capture Microdissection; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Oligonucleotide Array Sequence Analysis; Patient Selection; Phenotype; Precision Medicine; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Queensland; Quinazolines; ras Proteins; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Trastuzumab; Tumor Microenvironment; United States | 2012 |
[Management of patients with essential thrombocythemia].
Topics: Adult; Aged; Bone Marrow; Cytostatic Agents; Disease Management; Female; Genetic Predisposition to Disease; Hemorrhage; Humans; Interferon-alpha; Janus Kinase 2; Lactation; Male; Middle Aged; Platelet Aggregation Inhibitors; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential; Thrombophilia | 2013 |
From the bench to the bed: individualizing treatment in non-small-cell lung cancer.
Topics: 14-3-3 Proteins; Adenocarcinoma; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; DNA Damage; DNA Repair; Epistasis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Genes, BRCA1; Genes, cdc; Genes, erbB-1; Genes, ras; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Polymorphism, Genetic; Pyrimidines; Quinazolines | 2006 |
[Drug induced lung injuries in Japanese population].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Asian People; Bleomycin; Gefitinib; Genetic Predisposition to Disease; Humans; Isoxazoles; Japan; Leflunomide; Lung Diseases, Interstitial; Pulmonary Alveoli; Quinazolines; Racial Groups | 2006 |
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Diet; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pharmacogenetics; Quinazolines; Radiotherapy Dosage; Risk Factors; Smoking; Survival Analysis; Survivors; Tobacco Smoke Pollution; Treatment Outcome | 2008 |
10 trial(s) available for quinazolines and Genetic Predisposition
| Article | Year |
|---|---|
Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome | 2013 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Genetic Predisposition to Disease; Genotype; HLA-DRB1 Chains; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors | 2014 |
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin.
Topics: Alleles; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Genetic Predisposition to Disease; Humans; Linagliptin; Purines; Quinazolines; Transcription Factor 7-Like 2 Protein | 2014 |
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Europe; Female; Gefitinib; Genetic Predisposition to Disease; Glutamates; Guanine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
[Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Genetic Markers; Genetic Predisposition to Disease; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenomic Testing; Point Mutation; Prevalence; Quinazolines; Radiation Injuries; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2016 |
Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prevalence; Quinazolines; Risk Factors; Russia; Treatment Outcome | 2016 |
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Disease-Free Survival; Drug Administration Schedule; Female; France; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pedigree; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Risk Factors; Thyroid Neoplasms; Time Factors; Treatment Outcome; United States; Young Adult | 2010 |
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
31 other study(ies) available for quinazolines and Genetic Predisposition
| Article | Year |
|---|---|
RET-rearranged non-small-cell lung cancer and therapeutic implications.
Topics: Australia; Carcinoma, Non-Small-Cell Lung; Female; Gene Rearrangement; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Precision Medicine; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines | 2019 |
EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Nude; Puromycin; Pyrazines; Pyridines; Quinazolines; Rhabdomyosarcoma, Embryonal; RNA Interference; Wnt Signaling Pathway | 2020 |
Pulmonary fibrosis distal airway epithelia are dynamically and structurally dysfunctional.
Topics: Adaptor Proteins, Signal Transducing; Amphiregulin; Biophysical Phenomena; Epithelium; ErbB Receptors; Fibroblasts; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Keratin-5; Lung; Mucin-5B; Quinazolines; Risk Factors; RNA, Messenger; Signal Transduction; Transcription Factors; Tyrphostins; Verteporfin; YAP-Signaling Proteins | 2021 |
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Interleukin-6; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Prevalence; Quinazolines; Risk Factors; Survival Rate; Treatment Outcome | 2018 |
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Topics: Action Potentials; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic, Familial; Cell Differentiation; Cell Line; Cell Size; Cisapride; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Embryoid Bodies; Embryonic Stem Cells; Gene Expression Profiling; Genetic Predisposition to Disease; HEK293 Cells; Humans; In Vitro Techniques; Induced Pluripotent Stem Cells; Ion Channels; Kidney; Long QT Syndrome; Myocytes, Cardiac; Myofibrils; Nicorandil; Patch-Clamp Techniques; Quinazolines; Verapamil | 2013 |
Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence.
Topics: Adolescent; Adult; Afatinib; Aged; Animals; Behavior, Animal; Cyclic AMP Response Element-Binding Protein; DNA; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Hippocampus; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice; Middle Aged; Mutation; Neuregulins; Nicotine; Polymorphism, Single Nucleotide; Quinazolines; Rats; Receptor, ErbB-4; Smoking; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Tobacco Use Disorder; White People; Young Adult | 2014 |
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.
Topics: Alleles; Antineoplastic Agents; DNA; Drug Eruptions; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; HLA Antigens; Humans; Lapatinib; Polymorphism, Genetic; Quinazolines | 2015 |
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; China; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Nutrition Assessment; Nutritional Status; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Asian People; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Everolimus; Feasibility Studies; Female; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pilot Projects; Precision Medicine; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Sorafenib; Young Adult | 2016 |
Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Female; Gene Expression Profiling; Genes, Retinoblastoma; Genetic Predisposition to Disease; Humans; Lapatinib; Lymphangiogenesis; Male; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta | 2016 |
Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.
Topics: Alternative Splicing; Animals; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Genetic Predisposition to Disease; Humans; Inhibitory Concentration 50; Lapatinib; Mammary Neoplasms, Experimental; Mice, Transgenic; Phenotype; Protein Isoforms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Receptor, ErbB-2; Signal Transduction; Time Factors | 2016 |
Multiple primary lung cancer displaying different EGFR and PTEN molecular profiles.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Phenotype; Pneumonectomy; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients.
Topics: Acute Disease; Asian People; Gefitinib; Genetic Predisposition to Disease; Humans; Japan; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2008 |
Focus on ERBB2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Genetic Predisposition to Disease; Humans; Lapatinib; Polymorphism, Genetic; Protein Binding; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2008 |
Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Gene Frequency; Genetic Predisposition to Disease; Humans; Pancreatic Neoplasms; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Quinazolines; Time Factors; Tumor Cells, Cultured; Tyrphostins | 2008 |
Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Infusions, Intravenous; Lung Diseases, Interstitial; Lung Neoplasms; Methylprednisolone; Muscular Diseases; Prednisolone; Quinazolines | 2010 |
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Probability; Quinazolines; ras Proteins; Risk Assessment; White People | 2009 |
Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chemotherapy, Adjuvant; Cholecystitis; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; Genetic Predisposition to Disease; Humans; Incidental Findings; Lung Neoplasms; Mutation; Neoplasm Staging; Pedigree; Pneumonectomy; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vinblastine; Vinorelbine | 2010 |
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; HLA-DQ alpha-Chains; HLA-DQ Antigens; Humans; Lapatinib; Liver; Liver Diseases; Liver Function Tests; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2011 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Gefitinib; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Phenotype; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Next-generation cDNA screening for oncogene and resistance phenotypes.
Topics: Animals; Cell Line; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Library; Genes, erbB-2; Genetic Predisposition to Disease; Genetic Testing; Genetic Variation; Mice; Oncogenes; Phenotype; Protein Isoforms; Quinazolines | 2012 |
Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Quinazolines; Real-Time Polymerase Chain Reaction | 2012 |
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference; Small Ubiquitin-Related Modifier Proteins; Time Factors; Transfection; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Silencing; Genes, erbB-1; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Introns; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Skin | 2004 |
Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines; Tobacco Smoke Pollution | 2007 |
Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenomatosis, Pulmonary; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genes, erbB-1; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Mutation; Neoplasms, Multiple Primary; Quinazolines; Retrospective Studies | 2007 |
EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genetic Markers; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2008 |
Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injury.
Topics: Acrylamides; Adenoma; Animals; Anticarcinogenic Agents; Dose-Response Relationship, Drug; Duodenal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Female; Genes, APC; Genetic Predisposition to Disease; Growth Substances; Male; Mice; Mice, Inbred C57BL; Mucins; Muscle Proteins; Neuropeptides; Peptides; Phosphorylation; Protein Biosynthesis; Quinazolines; Signal Transduction; Trefoil Factor-2; Trefoil Factor-3 | 2000 |